AR
KRYS icon

Advisory Research’s Krystal Biotech KRYS Stock Holding History

Advisory Research’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,667
Closed -$703K – 250
2023
Q4 		$703K Sell
5,667
-3,322
-37% -$368K 0.11% 195
2023
Q3 		$1.04M Sell
8,989
-2,664
-23% -$325K 0.14% 190
2023
Q2 		$1.37M Buy
+11,653
New +$1.19M 0.18% 161
2023
Q1 		– Sell
-10,354
Closed -$820K – 384
2022
Q4 		$820K Sell
10,354
-465
-4% -$34.5K 0.08% 185
2022
Q3 		$754K Sell
10,819
-5,022
-32% -$363K 0.07% 187
2022
Q2 		$1.04M Sell
15,841
-2,890
-15% -$180K 0.1% 154
2022
Q1 		$1.25M Buy
18,731
+12,392
+195% +$773K 0.1% 165
2021
Q4 		$443K Buy
+6,339
New +$369K 0.03% 266

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Advisory Research's KRYS Position: Q1 2024 in Review

Advisory Research sold out of Krystal Biotech (KRYS) in Q1 2024, closing a stake of 5,667 shares — an estimated $703K sold.

Advisory Research first reported a position in KRYS in Q4 2021 and held it in 8 quarters. The position peaked at $1.37M in Q2 2023. 234 funds tracked by Wall St. Rank hold KRYS as of Q1 2024.

  • Advisory Research reported no remaining Krystal Biotech position as of Q1 2024 after selling out during the quarter.
  • Advisory Research sold 5,667 Krystal Biotech shares in Q1 2024, an estimated $703K.
  • Advisory Research first reported a position in Krystal Biotech in Q4 2021 and held it in 8 quarters.
  • Advisory Research's Krystal Biotech position peaked at $1.37M in Q2 2023.
  • 234 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2024.

Based on Advisory Research's 13F filing for Q1 2024, filed 14 May 2024.